trial · primary record
EBV gp350-ferritin vaccine with ALFQ adjuvant
EBV
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 750 |
| Primary completion | 2028-10-01 |
| Primary endpoint | Local and systemic reactogenicity signs and symptoms during the 7-day period after each vaccination. Unsolicited AEs up to 30 days after each vaccination and SAEs through Day 150. |
| Registry ID | NCT06908096 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:21.359Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06908096
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.